Daily Cardiology Research Analysis
Analyzed 103 papers and selected 3 impactful papers.
Summary
Three impactful cardiology studies stood out: a Circulation Research paper mechanistically links mitochondrial motility (via RHOT proteins) to cardiomyocyte sarcomere maturation; a prospective EuroIntervention study shows that stress haemodynamics (SAVI) unmasks high-risk physiology in moderate aortic stenosis, predicting need for valve intervention; and an International Journal of Cardiology study demonstrates that adding high-sensitivity troponin T to a clinical score markedly improves bedside identification of transthyretin cardiac amyloidosis in acute heart failure.
Research Themes
- Mitochondrial dynamics driving cardiomyocyte maturation
- Stress haemodynamics to refine risk in valvular heart disease
- Biomarker-augmented diagnostic scores for cardiac amyloidosis
Selected Articles
1. RHOT Proteins Link Mitochondrial Motility to Cardiomyocyte Sarcomere Maturation.
Using cardiomyocyte-selective RHOT1/2 knockout mice, the authors show that loss of RHOT-mediated mitochondrial motility causes fatal cardiomyopathy with sarcomere disarray and perinuclear mitochondrial accumulation, despite preserved respiratory capacity. Proteomics indicates RHOT proteins tether mitochondria to contractile fiber proteins, linking mitochondrial positioning with structural and functional maturation of the heart.
Impact: This mechanistic study uncovers a fundamental link between mitochondrial transport machinery and sarcomere maturation, advancing understanding of cardiac development and mitochondrial biology.
Clinical Implications: Although preclinical, the findings suggest that defects in mitochondrial positioning may underlie pediatric cardiomyopathies and could inform future therapies targeting mitochondrial trafficking.
Key Findings
- Cardiomyocyte-selective RHOT1/2 deletion caused fatal cardiomyopathy with sarcomere disarray.
- Mitochondria accumulated perinuclearly and showed impaired motility despite preserved respiratory capacity.
- Proteomics indicated RHOT proteins bind mitochondria to contractile muscle fiber proteins, supporting a tethering role.
Methodological Strengths
- Genetic cardiomyocyte-selective knockout enabling causal inference.
- Integration of phenotyping with proteomic analysis to identify binding partners.
Limitations
- Preclinical mouse model limits direct clinical generalizability.
- Abstract provides limited details on inducible adult deletion and rescue experiments.
Future Directions: Validate RHOT-dependent mitochondrial positioning in human iPSC-derived cardiomyocytes and investigate whether modulating RHOT–motor interactions can rescue developmental or pediatric cardiomyopathy phenotypes.
BACKGROUND: Cardiomyocyte mitochondria align with sarcomeres during heart development. Mitochondrial motility is controlled by RHOT (ras homolog family member T) 1 and RHOT2. RHOT1 and RHOT2 are atypical Rho-like small GTPases that are anchored to the outer mitochondrial membrane and couple mitochondria to kinesin and dynein motors. We hypothesized that RHOT protein expression and mitochondrial motility are required for mitochondrial positioning during cardiomyocyte development. METHODS: We generated mice with cardiomyocyte-selective deletion of RESULTS: cRhot1/2-KO mice developed fatal cardiomyopathy associated with sarcomere disarray and perinuclear accumulation of mitochondria and ATP production. Mitochondria isolated from cRhot1/2-KO hearts exhibited impaired motility but preserved respiratory capacity. Mechanistically, proteome analysis identified that RHOT proteins bind mitochondria to contractile muscle fiber proteins. In contrast, inducible deletion of CONCLUSIONS: RHOT proteins bind mitochondria to contractile muscle fiber proteins and are required for mitochondrial positioning in cardiomyocytes during development. Our study links mitochondrial motility and local ATP production to structural and functional maturation of the heart.
2. Clinical outcomes and haemodynamic response after blinded stress assessment of moderate aortic stenosis.
In a prospective, blinded study of 52 symptomatic moderate AS patients with preserved LVEF, stress haemodynamic assessment (SAVI) identified a high-risk subgroup (48% with SAVI ≤0.70) not recognized by resting AVA or calcium score. SAVI independently predicted aortic valve intervention (HR 5.7), suggesting that abnormal stress physiology in moderate AS may warrant earlier intervention.
Impact: Introduces a blinded, stress-based haemodynamic index that outperforms conventional metrics for risk stratification in moderate AS, with immediate implications for trial design and clinical decision-making.
Clinical Implications: Consider stress haemodynamic testing in symptomatic moderate AS with preserved LVEF to identify patients who may benefit from earlier valve intervention, beyond resting AVA or calcium thresholds.
Key Findings
- SAVI declined to a median of 0.70 under stress; 48% had SAVI ≤0.70 despite only moderate AS at rest.
- Resting AVA and sex-specific calcium thresholds failed to predict stress haemodynamics.
- Blinded SAVI independently predicted the need for aortic valve intervention (HR 5.7; p=0.007).
Methodological Strengths
- Prospective design with blinded SAVI assessment to avoid management bias.
- Comprehensive multimodal assessment (rest/stress echocardiography, dobutamine, bicycle, calcium scoring, invasive gradients).
Limitations
- Single-center pilot with small sample size limits generalizability.
- Outcome focused on valve intervention rather than hard endpoints such as mortality.
Future Directions: External validation and randomized trials testing SAVI-guided intervention thresholds versus standard care in moderate AS are warranted.
BACKGROUND: Assessing aortic stenosis (AS) haemodynamics under stress may distinguish physiological responses beyond traditional severity metrics. AIMS: We aimed to evaluate symptomatic patients with moderate AS and preserved left ventricular ejection fraction (LVEF) using invasive and non-invasive assessments at rest and during stress, hypothesising that the stress aortic valve index (SAVI) would show only modest agreement with echocardiographic parameters of AS severity but would be associated with clinical outcomes. METHODS: We prospectively enrolled 52 patients with moderate AS and preserved LVEF but who were symptomatic without an alternative explanation. The SAVI, quantifying the relative reduction in maximal flow, was measured but remained blinded. Comprehensive assessment included echocardiography (at rest, bicycle and dobutamine stress), calcium scoring, and clinical outcomes. Patients were managed according to current standards without knowledge of the SAVI and followed for ≥1 year. RESULTS: Invasive transvalvular gradient increased from 25±9 mmHg at rest to 42±14 mmHg during dobutamine. The aortic-to-left ventricular pressure ratio declined from 0.82 (interquartile range [IQR] 0.78-0.88) at rest to a SAVI of 0.70 (IQR 0.63-0.79) under stress. Resting aortic valve area (AVA) did not predict stress haemodynamics, underscoring physiological heterogeneity. Notably, 25/52 (48%) of patients demonstrated a SAVI ≤0.70, comparable with a severe AS cohort studied separately. Blinded SAVI scores independently predicted the need for clinical aortic valve (AV) intervention (hazard ratio 5.7; p=0.007), whereas AVA and sex-specific calcium thresholds did not. CONCLUSIONS: Stress haemodynamic assessment in moderate AS unmasks a subgroup, not identified by conventional metrics, who are at significantly higher risk for AV intervention. Patients with abnormal stress physiology despite only moderate AS at rest may benefit from AV intervention, supporting this pilot study as the basis for a future randomised trial.
3. Addition of high-sensitivity troponin to the T-Amylo score for the diagnosis of transthyretin cardiac amyloidosis in acute heart failure: TnT-Amylo.
In 138 consecutive AHF patients ≥60 years old, adding hs-TnT to the T-Amylo clinical score (TnT-Amylo) improved diagnostic stratification for ATTR-CM, particularly reclassifying the large intermediate-risk group. The revised model achieved high specificity (94.9%) and meaningful net reclassification improvement (135%), enabling more efficient targeting of bone scintigraphy.
Impact: Demonstrates a practical, low-cost augmentation to an existing score that can immediately refine bedside suspicion of ATTR-CM in AHF, streamlining advanced imaging pathways.
Clinical Implications: In hospitalized AHF patients, consider incorporating hs-TnT into clinical risk stratification to up- or down-classify intermediate-risk patients for ATTR-CM and prioritize bone scintigraphy accordingly.
Key Findings
- ATTR-CM prevalence was 15.9% among AHF patients aged ≥60 years.
- hs-TnT levels were significantly higher in ATTR-CM (median 68 vs 29 ng/L; p<0.001; AUC 0.80).
- In the intermediate-risk group, hs-TnT reclassified 15.7% to high risk (72.7% ATTR-CM) and 84.3% to low risk (5% ATTR-CM), yielding a net reclassification improvement of 135%.
Methodological Strengths
- Prospective single-centre enrollment with consecutive patients and blinded score calculation.
- Reference standard bone-tracer scintigraphy with plasma cell dyscrasia exclusion.
Limitations
- Single-centre design with modest sample size may introduce spectrum bias.
- No external validation; outcomes beyond diagnostic accuracy were not assessed.
Future Directions: External validation and multicentre implementation studies to test TnT-Amylo in diverse AHF populations and to evaluate downstream outcomes and cost-effectiveness.
BACKGROUND: Identifying specific aetiologies during hospitalization for acute heart failure (AHF) remains challenging, particularly conditions with important therapeutic and prognostic implications such as transthyretin cardiac amyloidosis (ATTR-CM). Clinical risk scores may aid early suspicion; however, many patients are classified as intermediate risk, limiting bedside decision-making in the acute care setting. High-sensitivity cardiac troponin T (hs-TnT) may improve diagnostic stratification. METHODS: We conducted a prospective single-centre study including consecutive patients aged ≥60 years hospitalized with AHF between 2022 and 2024. All patients underwent bone-tracer scintigraphy; ATTR-CM was defined by myocardial uptake grade ≥ 2 and exclusion of plasma cell dyscrasia. The T-Amylo score was calculated blinded to diagnosis. hs-TnT was incorporated into a revised model (TnT-Amylo) using regression-derived weighting. Patients were categorized as low (0-2), intermediate (3-6), or high (7-11) risk. Diagnostic performance and reclassification were evaluated. RESULTS: Among 138 patients (63% male; mean age 80 ± 6.9 years), ATTR-CM prevalence was 15.9%. The T-Amylo score showed good discrimination (AUC 0.93). hs-TnT was significantly higher in ATTR-CM than in non-ATTR-CM patients (median 68 vs 29 ng/L; p < 0.001; AUC 0.80). In the intermediate-risk group (n = 87), hs-TnT reclassified 15.7% to high risk (72.7% ATTR-CM) and 84.3% to low risk (5% ATTR-CM). The TnT-Amylo model achieved 72.3% sensitivity and 94.9% specificity, with a net reclassification improvement of 135%. CONCLUSIONS: In AHF patients, integrating hs-TnT into a clinical risk score improves bedside diagnostic stratification, particularly among intermediate-risk patients. This approach may facilitate early aetiological identification and more efficient use of advanced imaging in the acute cardiovascular care setting. TRANSLATIONAL PERSPECTIVE: This study translates pathophysiological insights of chronic myocardial injury in transthyretin cardiac amyloidosis into a simple bedside diagnostic tool. By integrating high-sensitivity cardiac troponin T-an inexpensive and universally available biomarker-into a clinical risk score, this approach bridges mechanistic myocardial damage with pragmatic decision-making, facilitating early identification of ATTR-CM and more efficient allocation of advanced imaging resources in acute heart failure care.